David M. Knott Jr’s Viking Therapeutics VKTX Stock Holding History

David M. Knott Jr’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-39,036	Closed	-$1.57M	–	98
2024 Q4	$1.57M	Hold	39,036	–	–	0.57%	25
2024 Q3	$2.47M	Sell	39,036 -37,000	-49%	-$2.17M	0.87%	25
2024 Q2	$4.03M	Sell	76,036 -25,400	-25%	-$1.66M	1.61%	14
2024 Q1	$8.32M	Sell	101,436 -169,386	-63%	-$7.54M	2.94%	7
2023 Q4	$5.04M	Buy	270,822 +85,267	+46%	+$1.12M	1.93%	11
2023 Q3	$2.05M	Buy	185,555 +110,006	+146%	+$1.57M	0.78%	24
2023 Q2	$1.23M	Sell	75,549 -124,615	-62%	-$2.61M	0.49%	37
2023 Q1	$3.33M	Sell	200,164 -181,457	-48%	-$1.87M	1.31%	16
2022 Q4	$3.59M	Buy	381,621 +79,818	+26%	+$356K	1.36%	17
2022 Q3	$821K	Buy	301,803 +35,000	+13%	+$115K	0.35%	51
2022 Q2	$771K	Buy	266,803 +38,701	+17%	+$95.8K	0.32%	56
2022 Q1	$684K	Buy	228,102 +20,000	+10%	+$71.7K	0.22%	70
2021 Q4	$957K	Buy	+208,102	New	+$1.17M	0.32%	53

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David M. Knott Jr's VKTX Position: Q1 2025 in Review

David M. Knott Jr sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 39,036 shares — an estimated $1.57M sold.

David M. Knott Jr first reported a position in VKTX in Q4 2021 and held it in 13 quarters. The position peaked at $8.32M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

David M. Knott Jr reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
David M. Knott Jr sold 39,036 Viking Therapeutics shares in Q1 2025, an estimated $1.57M.
David M. Knott Jr first reported a position in Viking Therapeutics in Q4 2021 and held it in 13 quarters.
David M. Knott Jr's Viking Therapeutics position peaked at $8.32M in Q1 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on David M. Knott Jr's 13F filing for Q1 2025, filed 12 May 2025.